18 completed, 6 terminated, 2 withdrawn. 12 Phase 2, 11 Phase 1, 5 Not applicable, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 9, Terminated 2, Withdrawn 1 |
| Phase 1 | 11 | Completed 7, Terminated 4 |
| Not applicable | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
Follow Noncutaneous Extranodal Lymphoma: new trials by email Literature Review of Noncutaneous Extranodal Lymphoma trials Research Report on Noncutaneous Extranodal Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma carmustine, cytarabine, melphalan - Adult Nasal Type Extranodal NK/T-cell Lymphoma, AIDS-related Diffuse Large Cell Lymphoma | Not applicable | Withdrawn | Fred Hutchinson Cancer Center | 2015-02-01 | 2015-05-07 | |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma 6,8-bis(benzylthio)octanoic acid, bendamustine hydrochloride - Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma | Phase 1 | Completed | Wake Forest University Health Sciences | 16 | 2014-09-01 | 2024-02-13 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant busulfan, etoposide, cyclophosphamide - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Early Phase 1 | Completed | Case Comprehensive Cancer Center | 33 | 2014-03-01 | 2015-08-13 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Completed | Morphotek | 27 | 2013-11-01 | 2016-01-08 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma plerixafor, filgrastim, etoposide - Adult Acute Lymphoblastic Leukemia in Remission, Adult Grade III Lymphomatoid Granulomatosis | Not applicable | Terminated | Case Comprehensive Cancer Center | 25 | 2011-10-01 | 2019-06-14 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies deferasirox, laboratory biomarker analysis, enzyme-linked immunosorbent assay - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Wake Forest University Health Sciences | 16 | 2011-01-01 | 2018-09-07 |
| MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Akt inhibitor MK2206, diagnostic laboratory biomarker analysis, pharmacological study - Accelerated Phase Chronic Myelogenous Leukemia, Acute Leukemias of Ambiguous Lineage | Phase 1 | Completed | National Cancer Institute (NCI) | 45 | 2011-01-01 | 2014-04-29 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Akt inhibitor MK2206, laboratory biomarker analysis - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 60 | 2010-12-01 | 2020-11-04 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy sunitinib malate, pharmacological study, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 1 | Completed | National Cancer Institute (NCI) | 42 | 2009-08-01 | 2014-03-17 |
| Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia dexrazoxane hydrochloride, doxorubicin hydrochloride, obatoclax mesylate - Acute Leukemias of Ambiguous Lineage, Acute Undifferentiated Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 22 | 2009-06-01 | 2014-05-01 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma bevacizumab, cediranib maleate - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 57 | 2007-05-01 | 2014-02-19 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer alemtuzumab, total-body irradiation, fludarabine phosphate - Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 12 | 2005-03-01 | 2017-05-30 |
| Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma oxaliplatin, etoposide - Angioimmunoblastic T-cell Lymphoma, B-cell Childhood Acute Lymphoblastic Leukemia | Phase 1 | Terminated | National Cancer Institute (NCI) | 40 | 2004-11-01 | 2014-02-24 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer fludarabine phosphate, total-body irradiation, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 150 | 2004-04-01 | 2020-01-29 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 1 / Phase 2 | Completed | Fred Hutchinson Cancer Center | 37 | 2003-09-01 | 2020-01-18 |
Showing 20 of 26. Sign in to see all of them.
Lymphoma, Extranodal NK-T-Cell (26) · Lymphoma, Large-Cell, Anaplastic (26) · Mycosis Fungoides (26) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (26) · Sezary Syndrome (26) · Immunoblastic Lymphadenopathy (25) · Lymphoma, Large B-Cell, Diffuse (25) · Lymphoma, T-Cell, Peripheral (25) · Burkitt Lymphoma (24) · Leukemia, Lymphocytic, Chronic, B-Cell (24) · Lymphoma, T-Cell, Cutaneous (24) · Intraocular Lymphoma (23) · Lymphoma, B-Cell, Marginal Zone (23) · Lymphoma, Follicular (23) · Lymphoma, Mantle-Cell (23)
Hematologic Diseases (26) · Hemic and Lymphatic Diseases (26) · Immune System Diseases (26) · Immunoproliferative Disorders (26) · Leukemia, Lymphoid (26) · Lymphatic Diseases (26) · Lymphoma, T-Cell (26) · Lymphoproliferative Disorders (26) · Neoplasms (26) · Neoplasms by Histologic Type (26) · Disease Attributes (25) · Leukemia (25) · Lymphadenopathy (25) · Lymphoma (25) · Lymphoma, B-Cell (25)
Peripheral Blood Stem Cell Transplantation (12) · Whole-Body Irradiation (9) · Mycophenolic Acid (8) · fludarabine phosphate (8) · Cyclosporine (7) · Etoposide (4) · Cyclophosphamide (3) · Rituximab (3) · Busulfan (2) · MK 2206 (2) · Tacrolimus (2) · Alemtuzumab (1) · Bendamustine Hydrochloride (1) · Bevacizumab (1) · Brentuximab Vedotin (1)
Fred Hutchinson Cancer Center (12) · National Cancer Institute (NCI) (6) · Case Comprehensive Cancer Center (2) · Wake Forest University Health Sciences (2) · Morphotek (1) · Northwestern University (1) · University of Chicago (1) · University of Medicine and Dentistry of New Jersey (1)
United States (26) · Italy (6) · Germany (3) · Canada (2)
David Maloney (4) · Ajay Gopal (2) · Ann Woolfrey (2) · Brenda Sandmaier (2) · Adam Petrich, MD (1) · Brian Hill, MD (1) · David Hong (1) · Hongtao Liu (1) · John Deeken (1) · Lisa McGregor (1) · Marco Mielcarek (1) · Mary Ann Knovich, MD (1) · Maryam Fouladi (1) · Mohamed Sorror (1) · Navneet Majhail, MD (1)
PMID 32499241, PMID 18698002, PMID 22259028, PMID 23393050, PMID 24474568, PMID 26213141, PMID 26764356, PMID 29292843
P30CA015704 (11), P01CA018029 (3), U01CA097452 (3), P01CA078902 (2), P30CA016672 (2), P30CA043703 (2), N01CM00039 (1), N01CM62202 (1), P01CA044991 (1), P30CA012197 (1), P30CA021765 (1), P30CA072720 (1), U01CA062461 (1), U01CA121947 (1)